- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01491399
INFUSE™ BONE GRAFT/CORNERSTONE-SR™ Allograft Ring/ATLANTIS™ Anterior Cervical Plate- Pilot Study
May 16, 2023 updated by: Medtronic Spinal and Biologics
Study of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the CORNERSTONE-SR™Allograft Ring and ATLANTIS™ Anterior Cervical Plate System in Treatment of Patients With Degenerative Cervical Disc Disease
The purpose of this clinical trial is to assess the safety and effectiveness of the Investigational implant as compared to the Control implant in the treatment of patients with one level or two adjacent levels of cervical symptomatic degenerative disc disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Cervical disc disease defined as: intractable radiculopathy and/or myelopathy with at least one of the following items producing symptomatic nerve root and/or spinal cord compression which is documented by diagnostic imaging procedures:
- herniated disc;
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration; and/or
- facet joint degeneration.
- Has preoperative Neck Disability Index score >= 30;
- C2-C3 disc to C7-Tl disc level(s) of involvement.
- One or two adjacent levels requiring fusion;
- No previous surgical intervention at the involved fusion level(s);
- Unresponsive to nonoperative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root or spinal cord compression in face of continued nonoperative management;
- Age > 18 years at time of surgery;
- Is female of child-bearing potential, who is not pregnant or nursing, and who agrees to not get pregnant for 1 year following surgery;
- Willingness to comply with study plan and sign the consent form.
Exclusion Criteria:
- Has cervical spinal condition requiring surgical treatment other than symptomatic cervical disc disease at the involved level(s).
- Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that anterior plating would be contraindicated.
- Has presence of spinal metastases.
- Has overt or active bacterial infection, either local or systemic.
- Has fever (temperature > 101°F oral) at the time of surgery.
- Has a documented titanium alloy allergy or intolerance.
- Is mentally incompetent. If questionable, obtain psychiatric consult.
- Is a prisoner.
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
- Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate), excluding routine perioperative anti-inflammatory drugs.
- Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Has a history of exposure to injectable collagen implants.
- Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
- Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
- Has received any previous exposure to any/all BMP's of either human or animal extraction.
- Has a history of allergy to bovine products or a history of anaphylaxis.
- Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).
- Has a condition which requires postoperative medications that interfere with fusion, such as steroids, excluding routine perioperative anti-inflammatory drugs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INFUSE™ Bone Graft/CORNERSTONE-SR™
|
Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
Other Names:
|
Active Comparator: Autogenous bone/CORNERSTONE-SR™
|
Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fusion
Time Frame: 24 month
|
Fusion is defined as:
|
24 month
|
Pain/Disability Status
Time Frame: 24 month
|
The self-administered Neck Disability Index will be used.
Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15
|
24 month
|
Neurological Status
Time Frame: 24 month
|
Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale.
|
24 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
General Health Status (SF-36)
Time Frame: 24 month
|
24 month
|
Patient Satisfaction
Time Frame: 24 month
|
24 month
|
Patient Global Perceived Effect
Time Frame: 24 month
|
24 month
|
Time to fusion
Time Frame: 24 month
|
24 month
|
Hip (Donor Site) Pain
Time Frame: 24 month
|
24 month
|
Pain Status (neck pain, arm pain)
Time Frame: 24 month
|
24 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 1999
Primary Completion (Actual)
March 1, 2003
Study Completion (Actual)
March 1, 2003
Study Registration Dates
First Submitted
December 12, 2011
First Submitted That Met QC Criteria
December 13, 2011
First Posted (Estimate)
December 14, 2011
Study Record Updates
Last Update Posted (Actual)
May 17, 2023
Last Update Submitted That Met QC Criteria
May 16, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-9702 Cornerstone ACDF pilot
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Cervical Disc Disease
-
Medtronic Spinal and BiologicsCompletedDegenerative Cervical Disc DiseaseSaudi Arabia, Greece, Serbia, Hungary, Czech Republic, Kuwait, Poland, Slovakia
-
Assiut UniversityNot yet recruiting
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
-
Medtronic Spinal and BiologicsCompletedCervical Degenerative Disc DiseaseUnited States
-
NuVasiveCompletedCervical Degenerative Disc DiseaseUnited States
-
Alphatec Spine, Inc.Terminated
Clinical Trials on INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™
-
Medtronic Spinal and BiologicsTerminatedDegenerative Cervical Disc Disease
-
Medtronic Spinal and BiologicsRecruitingIntervertebral Disc Degeneration | Spinal Fusion | Lumbar Disc DiseaseKorea, Republic of
-
Medtronic Spinal and BiologicsRecruitingDegenerative Disease of the Lumbosacral SpineUnited States, China
-
Medtronic Spinal and BiologicsCompletedDegenerative Disc Disease
-
Medtronic Spinal and BiologicsCompleted
-
Zetagen Therapeutics, IncRecruitingMetastatic Breast Cancer in the SpineCanada
-
Medtronic Spinal and BiologicsCompleted
-
Lombard MedicalSuspendedAbdominal Aortic AneurysmsUnited Kingdom, Germany, New Zealand, Spain, Czechia, Italy
-
Hospital for Special Surgery, New YorkAvailableArthroplasty of the PIP JointUnited States
-
Hospital for Special Surgery, New YorkApproved for marketingArthroplasty of the MCP JointUnited States